RxDoctor Payments DataLook up a doctor →

David Riseberg, MD

Medical Oncology · Baltimore, MDNPI 1124133210

Payments from drug & device makers

$4,038,455in general payments, 2019–2025

Across 964 payments — averaging $4189.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2M
  • Pfizer$629K
  • Genentech, Inc.$604K
  • Seagen Inc.$296K
  • AstraZeneca$231K
  • Merck$91K
  • plus $218K from 54 others
$330in research payments, 2019–2025

Across 1 payment — averaging $330.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$330

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis116$1,969,340
Pfizer94$629,383
Genentech, Inc.158$603,925
Seagen Inc.56$295,721
AstraZeneca(2 entities)44$230,870
Merck28$90,805
Gilead(2 entities)77$71,578
Amgen20$59,452
Macrogenics, Inc.7$29,776
Radius Health, Inc.6$15,703
Puma Biotechnology, Inc.15$15,460
Roche Products Limited9$11,656
Daiichi Sankyo Inc.18$3,314
Immunomedics, Inc.1$2,398
E.r. Squibb & Sons, L.L.C.37$1,254
Hoffmann-la Roche Limited1$1,000
Johnson & Johnson30$707
Incyte Corporation18$497
Genentech USA, Inc.19$402
Lilly USA, LLC16$322
GSK13$303
Bayer9$252
AbbVie11$243
Beigene USA, Inc.5$241
Intera Oncology, Inc1$228
Pharmaessentia USA Corporation9$217
EMD Serono, Inc.10$184
Regeneron Healthcare Solutions, Inc.5$183
Pharmacyclics LLC, An Abbvie Company7$154
Bristol Myers Squibb7$153
Caris MPI, Inc.2$148
Sanofi7$148
Array Biopharma Inc7$147
Eisai Inc.3$144
Boehringer Ingelheim6$133
Taiho Oncology, Inc.5$126
Advanced Accelerator Applications1$113
Astellas Pharma US Inc6$111
Genmab U.S., Inc.4$108
Rigel Pharmaceuticals, Inc.5$100
Takeda Pharmaceuticals U.S.A., Inc.4$98
Tesaro, Inc.4$93
Shire North American Group Inc6$90
Ipsen Biopharmaceuticals, Inc4$76
Bio Products Laboratory USA, Inc.5$65
Tersera Therapeutics LLC3$65
Jazz Pharmaceuticals Inc.2$60
Foundation Medicine, Inc.3$60
Pharmacosmos Therapeutics Inc.2$57
Exelixis Inc.3$57
Stemline Therapeutics Inc.2$50
Mirati Therapeutics, Inc.2$42
ADC Therapeutics America, Inc.2$42
AMAG Pharmaceuticals, Inc.3$39
AVEO Pharmaceuticals, Inc.1$37
Clovis Oncology, Inc.2$32
Servier Pharmaceuticals LLC2$32
Beone Medicines USA, Inc.1$29
Iovance Biotherapeutics, Inc.1$29
Menarini Silicon Biosystems, Inc.1$27

How this compares

$4,038,455 in reported general payments places this provider in the 90th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$1,909,333
Medicare patients
1,045
Services billed
93,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Baltimore

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →